A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
← catalyst calendarNCT07148089 · readout ≤ 315 d
Sponsored by Solid Biosciences Inc. (industry) · SLDB — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
18estimated
Sites
5
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-23 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Catecholaminergic Polymorphic Ventricular Tachycardia
Intervention
- Drug: SGT-501
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment-Emergent Adverse Event (TEAEs)s through Day 360
measured First dose through Day 360
Permalink · SLDB's whole pipeline · Catalyst calendar · Every registered study · What changed